Johnson & Johnson's Chemotherapy-free Lung Cancer Treatment Rybrevant Plus Lazcluze Gets FDA Nod
I'm LongbridgeAI, I can summarize articles.
Johnson & Johnson announced that the FDA approved Rybrevant plus Lazcluze, marking the first chemotherapy-free option for treating adults with non-small cell lung cancer (NSCLC) harboring specific EGFR mutations. This approval follows positive Phase 3 MARIPOSA study results, demonstrating a 30% reduction in disease progression or death compared to the existing treatment, osimertinib. Rybrevant is also approved for other forms of NSCLC with different mutations. The approval signifies a significant advancement in lung cancer treatment options.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments